ClinicalTrials.gg
CompletedNCT00545714Updated Jan 16, 2019Results posted

A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)

A Phase 2 interventional study of Cyclophosphamide and Fludarabine in Leukemia, Lymphocytic, Chronic, B-Cell, sponsored by Hoffmann-La Roche. Completed at 33 sites in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-01-16.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell — 3 open to participants now, 11 under way, none of them phase 3. Cyclophosphamide · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
39th of 145
86 · median 49
Started
2007
with 7 others
Phase 2
100 of 155
1 open now
Registered
74th of 155
by date
Lead sponsor
7 of 155
Hoffmann-La Roche

Among the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 39th largest by enrollment of the 145 interventional ones that give a count, is one of 8 that started in 2007, is one of 100 in phase 2, and was the 74th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 237 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

3 of the 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About cyclophosphamide

Cyclophosphamide: first FDA approval 1959 (CYTOXAN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 188 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 155 studies testing cyclophosphamide in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

This single arm study will assess the efficacy and safety of rituximab in combination with fludarabine and cyclophosphamide, followed by rituximab maintenance therapy, as first line treatment of participants with CLL.

03

Conditions studied

  • Leukemia, Lymphocytic, Chronic, B-Cell
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • CLL according to World Health Organization diagnostic criteria
  • Active disease
  • No previous treatment
  • (ECOG) performance status of 0, 1, or 2

Exclusion criteria

Exclusion Criteria:

  • Transformation to aggressive B-cell (prolymphocytic leukemia, large-cell lymphoma, Hodgkin's lymphoma)
  • Other malignancies except for localized skin cancer
  • Continuous systemic treatment
  • Known infection with or C
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    Rituximab + Fludarabine + Cyclophosphamide

    Participants will receive 6 cycles (cycle length = 28 days) of treatment with rituximab (375 milligrams per square meter \[mg/m\^2\] as intravenous \[IV\] infusion on Day 0 of Cycle 1 and 500 mg/m\^2 as IV infusion on Day 1 of Cycles 2-6); fludarabine (25 mg/m\^2 on Days 1-3) and cyclophosphamide (250 mg/m\^2 on Days 1-3). Participants with a partial or complete response and appropriate neutrophil conditions will receive maintenance treatment with rituximab (375 mg/m\^2 as IV infusion every 2 months) from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.

    Drug: Cyclophosphamide · Drug: Fludarabine · Drug: Rituximab

Interventions

  • Cyclophosphamide 250 mg/m\^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.

  • Fludarabine 25 mg/m\^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.

  • Rituximab 375 mg/m\^2 as IV infusion will be administered on Day 0 of Cycle 1; 500 mg/m\^2 as IV infusion will be administered on Day 1 of Cycle 2-6; and 375 mg/m\^2 as IV infusion every 2 months from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.

    Also known as: MabThera, Rituxan

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With CR Achieved After the Rituximab, Fludarabine, and Cyclophosphamide Regimen

    CR was defined as no adenopathies (ADPs) and visceromegalies (VSMs) in physical examination (PE); no general symptoms (Sx); lymphocytes (Lymph) in peripheral blood less than (\<) 4000 per cubic millimeter (mm\^3); normalization of peripheral blood parameters: neutrophils (Neut) greater than (\>) 1500/mm\^3, platelets (Plt) \>100,000/mm\^3, hemoglobin (Hb) \>11 grams per deciliter (g/dL) without transfusion; normocellular bone marrow (BM) with \<30% Lymph; BM aspirate/biopsy with no evidence of infiltration of lymphoid nodules.

    Time frame: Month 9

Secondary outcomes

  1. Percentage of Participants With Clinical Response of CR or PR as Assessed by Multiparameter Flow Cytometry

    CR was defined as no ADPs and VSMs in PE; no general Sx; Lymph in peripheral blood \<4000/mm\^3; normalization of peripheral blood parameters: Neut \>1500/mm\^3, Plt \>100,000/mm\^3, Hb \>11 g/dL without transfusion; normocellular BM with \<30% Lymph; BM aspirate/biopsy with no evidence of infiltration of lymphoid nodules. PR was defined as decrease \>50% in Lymph in peripheral blood; reduction in ADPs \>50% in total sum of up to 6 ADPs or in the baseline ADP of largest diameter (LD), no new ADP or enlargement of a prior ADP; \>50% decrease in VSM; Neut \>1500/mm\^3 or \>50% increase from Baseline; Plt \>100,000/mm\^3 or \>50% increase from Baseline; Hb \>11.0 g/dL or \>50% increase from Baseline value without transfusion. Participants who met all CR criteria but had persistent anemia or thrombocytopenia were considered as PR.

    Time frame: Post-Induction Phase (IP): at 6 months; during Maintenance Phase (MP): at Cycles 9, 12, 15, 18 (cycle length = 2 months); during Follow-Up (FU): at Follow-Up Months 6, 12, 18, 24, 30, 36

  2. Percentage of Participants With Clinical Response of CR or PR Among Participants With Negative Minimal Residual Disease (MRD) as Assessed by Multiparameter Flow Cytometry

    CR: no ADPs and VSMs in PE; no general Sx; Lymph in peripheral blood \<4000/mm\^3; normalization of peripheral blood parameters: Neut \>1500/mm\^3, Plt \>100,000/mm\^3, Hb \>11 g/dL without transfusion; normocellular BM with \<30% Lymph; BM aspirate/biopsy with no evidence of infiltration of lymphoid nodules. PR: decrease \>50% in Lymph in peripheral blood; reduction in ADPs \>50% in total sum of up to 6 ADPs or in the baseline ADP of largest diameter (LD), no new ADP or enlargement of a prior ADP; \>50% decrease in VSM; Neut \>1500/mm\^3 or \>50% increase from Baseline; Plt \>100,000/mm\^3 or \>50% increase from Baseline; Hb \>11.0 g/dL or \>50% increase from Baseline value without transfusion. Participants who met all CR criteria but had persistent anemia or thrombocytopenia were considered as PR. Negative MRD: Lymph \<0.01% of all white blood cells (WBCs) in blood or BM after two consecutive measurements. Analysis performed only in blood during the Maintenance Phase and Follow-Up.

    Time frame: Post-Induction Phase: at 6 months; during Maintenance Phase: at Cycles 9, 12, 15, 18 (cycle length = 2 months); during Follow-Up: at Follow-Up Months 6, 12, 18, 24, 36

  3. Percentage of Participants With CR With Incomplete Bone Marrow Recovery (CRi)

    Participants with CRi were those who met all CR criteria (including BM examinations) but had persistent anemia, thrombocytopenia, or neutropenia apparently unrelated to chronic lymphocytic leukemia (CLL) but related to drug toxicity. CR: no ADPs and VSMs in PE; no general Sx; Lymph in peripheral blood \<4000/mm\^3; normalization of peripheral blood parameters: Neut \>1500/mm\^3, Plt \>100,000/mm\^3, Hb \>11 g/dL without transfusion; normocellular BM with \<30% Lymph; BM aspirate/biopsy with no evidence of infiltration of lymphoid nodules.

    Time frame: Baseline up to progressive disease (PD) or death due to any cause, whichever occurred first (up to 92 months)

  4. Percentage of Participants Who Died

    Time frame: Baseline up to death due to any cause (up to 92 months)

  5. Overall Survival (OS)

    OS was defined as time from treatment start to death of the participant. For all other participants, the last follow-up available was taken as the last control. If the participant had not completed the study, the date of the last visit available was considered. OS was estimated using Kaplan-Meier (KM) methodology.

    Time frame: Baseline up to death due to any cause (up to 92 months)

  6. Percentage of Participants With PD or Death

    PD was defined as new ADPs (1.5 centimeters \[cm\]), hepato-/splenomegaly (HSM), Richter syndrome (RS), or other infiltrated organs; greater than or equal to (\>/=) 50% increase in size of Baseline prior ADPs or HSM in participants with PR; Lymph increase \>/=50% in peripheral blood with B Lymph \>/=5000/mm\^3; cytopenia attributable to CLL. Progression of any cytopenia (not related to autoimmune cytopenia) reported as a 2-g/dL decrease in basal Hb, Hb \<10 g/dL, \>/=50% decrease in basal Plt count, or count \<100,000/mm\^3 at \>/=3 months post-treatment was defined as PD if BM biopsy confirmed infiltration of clonal CLL cells.

    Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to 92 months)

  7. Progression-Free Survival (PFS)

    PFS was defined as time from start of study treatment to PD or death, whichever occurred first. For other participants, last follow-up available was taken as last control. If participant did not complete study, date of last visit available was considered. PFS was estimated using KM methodology. PD was defined as new ADPs (1.5 cm), HSM, RS, or other infiltrated organs; \>/=50% increase in size of Baseline prior ADPs or HSM in participants with PR; Lymph increase \>/=50% in peripheral blood with B Lymph \>/=5000/mm\^3; cytopenia attributable to CLL. Progression of any cytopenia (not related to autoimmune cytopenia) reported as a 2-g/dL decrease in basal Hb, Hb \<10 g/dL, \>/=50% decrease in basal Plt count, or count \<100,000/mm\^3 at \>/=3 months post-treatment was defined as PD if BM biopsy confirmed infiltration of clonal CLL cells.

    Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to 92 months)

  8. Treatment-Free Survival (TFS)

    TFS was defined time from start of study treatment until participant received new chemotherapy/immunotherapy because of PD and to reduce the disease with palliative or curative intent. PD was defined as new ADPs (1.5 cm), HSM, RS, or other infiltrated organs; \>/=50% increase in size of Baseline prior ADPs or HSM in participants with PR; Lymph increase \>/=50% in peripheral blood with B Lymph \>/=5000/mm\^3; cytopenia attributable to CLL. Progression of any cytopenia (not related to autoimmune cytopenia) reported as a 2-g/dL decrease in basal Hb, Hb \<10 g/dL, \>/=50% decrease in basal Plt count, or count \<100,000/mm\^3 at \>/=3 months post-treatment was defined as PD if BM biopsy confirmed infiltration of clonal CLL cells.

    Time frame: Baseline up to PD or death due to any cause, whichever occurred first (up to 92 months)

  9. Duration of Response (DOR)

    DOR: time from CR/PR to MRD/PD. PD: new ADP (1.5 cm), HSM, RS, other infiltrated organs or \>/=50% increase size in those with PR; blood Lymph increase \>/=50% with B Lymph \>/=5000/mm\^3; cytopenia due to CLL. Progression of (nonautoimmune) cytopenia: 2-g/dL decrease basal Hb, Hb \<10 g/dL, \>/=50% decrease basal Plt or \<100,000/mm\^3 at \>/=3 months post-treatment was PD if clonal CLL cell infiltration on BM biopsy. CR: no ADP/VSM in PE; no general Sx; blood Lymph \<4000/mm\^3; Neut \>1500/mm\^3; Plt \>100,000/mm\^3; Hb \>11 g/dL (no transfusion); normocellular BM with \<30% Lymph; BM aspirate/biopsy with no lymphoid nodule infiltration. PR: \>50% decrease blood Lymph; \>50% decrease in total sum up to 6 ADPs or baseline ADP of LD, no new/enlargement of prior ADP; \>50% decrease VSM; Neut \>1500/mm\^3 or \>50% increase; Plt \>100,000/mm\^3 or \>50% increase; Hb \>11.0 g/dL or \>50% increase (no transfusion). All CR criteria but persistent anemia or thrombocytopenia was PR. MRD: Lymph \>0.01% of blood/BM WBCs.

    Time frame: From first CR or PR up to detectable MRD or disease occurrence/PD, whichever occurred first (up to 92 months)

  10. Percentage of Participants With Cluster of Differentiation (CD) 38 Cells >/=30% in Peripheral Blood

    Percentages of participants with CD38 expression by \>/=30% of CLL cells during the Induction Phase, Maintenance Phase, and Follow-Up were reported.

    Time frame: Post-Induction Phase: at 6 months; during Maintenance Phase: at Cycles 9, 12, 15, 18 (cycle length = 2 months); during Follow-Up: at Follow-Up Months 6, 12, 18, 24, 30, 36

  11. Percentage of Participants With Genetic Abnormalities

    Percentages of participants with genetic abnormalities (deletion 6q, deletion 11q22-q23, deletion p53, trisomy 12, and deletion 13q14) in the course of the disease during the Induction Phase and Maintenance Phase were reported.

    Time frame: Post-Induction Phase: at 6 months; during Maintenance Phase: at Cycles 9, 12, 15, 18 (cycle length = 2 months)

  12. Percentage of Participants With Positive and Negative Zeta-Chain-Associated Protein Kinase 70 (ZAP-70) Expression

    Percentages of participants with positive and negative ZAP-70 expression during the Induction Phase, Maintenance Phase, and Follow-Up were reported. Positive ZAP-70 was defined as ZAP-70 expression by \>/=20% of CLL cells. Negative ZAP-70 was defined as ZAP-70 expression by \<20% of CLL cells.

    Time frame: Post-Induction Phase: at 6 months; during Maintenance Phase: at Cycles 9, 12, 15, 18 (cycle length = 2 months); during Follow-Up: at Follow-Up Months 6, 12, 18, 24, 30, 36

  13. Percentage of Participants With Immunoglobulin Heavy Locus (IgH) Rearrangement

    Percentages of participants with IgH rearrangement during the Induction Phase, Maintenance Phase, and Follow-Up were reported.

    Time frame: Post-Induction Phase: at 6 months; during Maintenance Phase: at Cycles 9, 12, 15, 18 (cycle length = 2 months); during Follow-Up: at Follow-Up Months 6, 12, 18, 24, 30, 36

07

Results

Posted Jan 16, 2019

Participant flow

Induction Phase (6 Months)
Participant flow — Induction Phase (6 Months)
MilestoneRituximab + Fludarabine + Cyclophosphamide
Started86
Safety population86
Intent-to-treat (itt) population84
Completed74
Not completed12
Withdrew: Physician decision3
Withdrew: Unacceptable toxicity6
Withdrew: Disease progression1
Withdrew: Eligibility criteria violation2
Maintenance Phase (36 Months)
Participant flow — Maintenance Phase (36 Months)
MilestoneRituximab + Fludarabine + Cyclophosphamide
Started74
Completed42
Not completed32
Withdrew: Unacceptable toxicity16
Withdrew: Disease progression9
Withdrew: Physician decision1
Withdrew: Protocol violation1
Withdrew: Withdrawal by subject3
Withdrew: Death2

Outcome measures

PrimaryPercentage of Participants With CR Achieved After the Rituximab, Fludarabine, and Cyclophosphamide Regimen

CR was defined as no adenopathies (ADPs) and visceromegalies (VSMs) in physical examination (PE); no general symptoms (Sx); lymphocytes (Lymph) in peripheral blood less than (\<) 4000 per cubic millimeter (mm\^3); normalization of peripheral blood parameters: neutrophils (Neut) greater than (\>) 1500/mm\^3, platelets (Plt) \>100,000/mm\^3, hemoglobin (Hb) \>11 grams per deciliter (g/dL) without transfusion; normocellular bone marrow (BM) with \<30% Lymph; BM aspirate/biopsy with no evidence of infiltration of lymphoid nodules.

Time frame:
Month 9
Reported as:
Number · Percentage of Participants
Percentage of Participants With CR Achieved After the Rituximab, Fludarabine, and Cyclophosphamide Regimen
Percentage of ParticipantsRituximab + Fludarabine + Cyclophosphamide
Percentage of Participants With CR Achieved After the Rituximab, Fludarabine, and Cyclophosphamide Regimen95.2 (88.25 to 98.69)
SecondaryPercentage of Participants With Clinical Response of CR or PR as Assessed by Multiparameter Flow Cytometry

CR was defined as no ADPs and VSMs in PE; no general Sx; Lymph in peripheral blood \<4000/mm\^3; normalization of peripheral blood parameters: Neut \>1500/mm\^3, Plt \>100,000/mm\^3, Hb \>11 g/dL without transfusion; normocellular BM with \<30% Lymph; BM aspirate/biopsy with no evidence of infiltration of lymphoid nodules. PR was defined as decrease \>50% in Lymph in peripheral blood; reduction in ADPs \>50% in total sum of up to 6 ADPs or in the baseline ADP of largest diameter (LD), no new ADP or enlargement of a prior ADP; \>50% decrease in VSM; Neut \>1500/mm\^3 or \>50% increase from Baseline; Plt \>100,000/mm\^3 or \>50% increase from Baseline; Hb \>11.0 g/dL or \>50% increase from Baseline value without transfusion. Participants who met all CR criteria but had persistent anemia or thrombocytopenia were considered as PR.

Time frame:
Post-Induction Phase (IP): at 6 months; during Maintenance Phase (MP): at Cycles 9, 12, 15, 18 (cycle length = 2 months); during Follow-Up (FU): at Follow-Up Months 6, 12, 18, 24, 30, 36
Reported as:
Number · Percentage of Participants
Percentage of Participants With Clinical Response of CR or PR as Assessed by Multiparameter Flow Cytometry
Percentage of ParticipantsRituximab + Fludarabine + Cyclophosphamide
Post-IP: CR75.0
Post-IP: PR13.1
MP (9 Cycles): CR89.4
MP (9 Cycles): PR6.4
MP (12 Cycles): CR87.9
MP (12 Cycles): PR6.1
MP (15 Cycles): CR90.9
MP (15 Cycles): PR4.5
MP (18 Cycles): CR88.1
MP (18 Cycles): PR8.5
6 Months FU: CR83.3
6 Months FU: PR0.0
12 Months FU: CR94.4
12 Months FU: PR0.0
18 Months FU: CR100.0
18 Months FU: PR0.0
24 Months FU: CR93.1
24 Months FU: PR0.0
30 Months FU: CR100.0
30 Months FU: PR0.0
36 Months FU: CR100.0
36 Months FU: PR0.0
SecondaryPercentage of Participants With Clinical Response of CR or PR Among Participants With Negative Minimal Residual Disease (MRD) as Assessed by Multiparameter Flow Cytometry

CR: no ADPs and VSMs in PE; no general Sx; Lymph in peripheral blood \<4000/mm\^3; normalization of peripheral blood parameters: Neut \>1500/mm\^3, Plt \>100,000/mm\^3, Hb \>11 g/dL without transfusion; normocellular BM with \<30% Lymph; BM aspirate/biopsy with no evidence of infiltration of lymphoid nodules. PR: decrease \>50% in Lymph in peripheral blood; reduction in ADPs \>50% in total sum of up to 6 ADPs or in the baseline ADP of largest diameter (LD), no new ADP or enlargement of a prior ADP; \>50% decrease in VSM; Neut \>1500/mm\^3 or \>50% increase from Baseline; Plt \>100,000/mm\^3 or \>50% increase from Baseline; Hb \>11.0 g/dL or \>50% increase from Baseline value without transfusion. Participants who met all CR criteria but had persistent anemia or thrombocytopenia were considered as PR. Negative MRD: Lymph \<0.01% of all white blood cells (WBCs) in blood or BM after two consecutive measurements. Analysis performed only in blood during the Maintenance Phase and Follow-Up.

Time frame:
Post-Induction Phase: at 6 months; during Maintenance Phase: at Cycles 9, 12, 15, 18 (cycle length = 2 months); during Follow-Up: at Follow-Up Months 6, 12, 18, 24, 36
Reported as:
Number · Percentage of Participants
Percentage of Participants With Clinical Response of CR or PR Among Participants With Negative Minimal Residual Disease (MRD) as Assessed by Multiparameter Flow Cytometry
Percentage of ParticipantsRituximab + Fludarabine + Cyclophosphamide
Post-IP: Blood MRD Negative100.0
Post-IP: BM MRD Negative100.0
MP (9 Cycles): Blood MRD Negative100.0
MP (12 Cycles): Blood MRD Negative100.0
MP (15 Cycles): Blood MRD Negative100.0
MP (18 Cycles): Blood MRD Negative100.0
6 Months FU: Blood MRD Negative100.0
12 Months FU: Blood MRD Negative100.0
18 Months FU: Blood MRD Negative100.0
24 Months FU: Blood MRD Negative100.0
36 Months FU: Blood MRD Negative100.0
SecondaryPercentage of Participants With CR With Incomplete Bone Marrow Recovery (CRi)

Participants with CRi were those who met all CR criteria (including BM examinations) but had persistent anemia, thrombocytopenia, or neutropenia apparently unrelated to chronic lymphocytic leukemia (CLL) but related to drug toxicity. CR: no ADPs and VSMs in PE; no general Sx; Lymph in peripheral blood \<4000/mm\^3; normalization of peripheral blood parameters: Neut \>1500/mm\^3, Plt \>100,000/mm\^3, Hb \>11 g/dL without transfusion; normocellular BM with \<30% Lymph; BM aspirate/biopsy with no evidence of infiltration of lymphoid nodules.

Time frame:
Baseline up to progressive disease (PD) or death due to any cause, whichever occurred first (up to 92 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With CR With Incomplete Bone Marrow Recovery (CRi)
Percentage of ParticipantsRituximab + Fludarabine + Cyclophosphamide
Percentage of Participants With CR With Incomplete Bone Marrow Recovery (CRi)7.1
SecondaryPercentage of Participants Who Died
Time frame:
Baseline up to death due to any cause (up to 92 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Died
Percentage of ParticipantsRituximab + Fludarabine + Cyclophosphamide
Percentage of Participants Who Died23.2 (5.72 to NA)
SecondaryOverall Survival (OS)

OS was defined as time from treatment start to death of the participant. For all other participants, the last follow-up available was taken as the last control. If the participant had not completed the study, the date of the last visit available was considered. OS was estimated using Kaplan-Meier (KM) methodology.

Time frame:
Baseline up to death due to any cause (up to 92 months)
Reported as:
Median · Years
Overall Survival (OS)
YearsRituximab + Fludarabine + Cyclophosphamide
Overall Survival (OS)7.51 (7.5 to NA)
SecondaryPercentage of Participants With PD or Death

PD was defined as new ADPs (1.5 centimeters \[cm\]), hepato-/splenomegaly (HSM), Richter syndrome (RS), or other infiltrated organs; greater than or equal to (\>/=) 50% increase in size of Baseline prior ADPs or HSM in participants with PR; Lymph increase \>/=50% in peripheral blood with B Lymph \>/=5000/mm\^3; cytopenia attributable to CLL. Progression of any cytopenia (not related to autoimmune cytopenia) reported as a 2-g/dL decrease in basal Hb, Hb \<10 g/dL, \>/=50% decrease in basal Plt count, or count \<100,000/mm\^3 at \>/=3 months post-treatment was defined as PD if BM biopsy confirmed infiltration of clonal CLL cells.

Time frame:
Baseline up to PD or death due to any cause, whichever occurred first (up to 92 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With PD or Death
Percentage of ParticipantsRituximab + Fludarabine + Cyclophosphamide
Percentage of Participants With PD or Death39.29 (5.72 to NA)
SecondaryProgression-Free Survival (PFS)

PFS was defined as time from start of study treatment to PD or death, whichever occurred first. For other participants, last follow-up available was taken as last control. If participant did not complete study, date of last visit available was considered. PFS was estimated using KM methodology. PD was defined as new ADPs (1.5 cm), HSM, RS, or other infiltrated organs; \>/=50% increase in size of Baseline prior ADPs or HSM in participants with PR; Lymph increase \>/=50% in peripheral blood with B Lymph \>/=5000/mm\^3; cytopenia attributable to CLL. Progression of any cytopenia (not related to autoimmune cytopenia) reported as a 2-g/dL decrease in basal Hb, Hb \<10 g/dL, \>/=50% decrease in basal Plt count, or count \<100,000/mm\^3 at \>/=3 months post-treatment was defined as PD if BM biopsy confirmed infiltration of clonal CLL cells.

Time frame:
Baseline up to PD or death due to any cause, whichever occurred first (up to 92 months)
Reported as:
Median · Years
Progression-Free Survival (PFS)
YearsRituximab + Fludarabine + Cyclophosphamide
Progression-Free Survival (PFS)6.96 (5.72 to NA)
SecondaryTreatment-Free Survival (TFS)

TFS was defined time from start of study treatment until participant received new chemotherapy/immunotherapy because of PD and to reduce the disease with palliative or curative intent. PD was defined as new ADPs (1.5 cm), HSM, RS, or other infiltrated organs; \>/=50% increase in size of Baseline prior ADPs or HSM in participants with PR; Lymph increase \>/=50% in peripheral blood with B Lymph \>/=5000/mm\^3; cytopenia attributable to CLL. Progression of any cytopenia (not related to autoimmune cytopenia) reported as a 2-g/dL decrease in basal Hb, Hb \<10 g/dL, \>/=50% decrease in basal Plt count, or count \<100,000/mm\^3 at \>/=3 months post-treatment was defined as PD if BM biopsy confirmed infiltration of clonal CLL cells.

Time frame:
Baseline up to PD or death due to any cause, whichever occurred first (up to 92 months)
Reported as:
Median · Years
Treatment-Free Survival (TFS)
YearsRituximab + Fludarabine + Cyclophosphamide
Treatment-Free Survival (TFS)4.13 (2.98 to 4.87)
SecondaryDuration of Response (DOR)

DOR: time from CR/PR to MRD/PD. PD: new ADP (1.5 cm), HSM, RS, other infiltrated organs or \>/=50% increase size in those with PR; blood Lymph increase \>/=50% with B Lymph \>/=5000/mm\^3; cytopenia due to CLL. Progression of (nonautoimmune) cytopenia: 2-g/dL decrease basal Hb, Hb \<10 g/dL, \>/=50% decrease basal Plt or \<100,000/mm\^3 at \>/=3 months post-treatment was PD if clonal CLL cell infiltration on BM biopsy. CR: no ADP/VSM in PE; no general Sx; blood Lymph \<4000/mm\^3; Neut \>1500/mm\^3; Plt \>100,000/mm\^3; Hb \>11 g/dL (no transfusion); normocellular BM with \<30% Lymph; BM aspirate/biopsy with no lymphoid nodule infiltration. PR: \>50% decrease blood Lymph; \>50% decrease in total sum up to 6 ADPs or baseline ADP of LD, no new/enlargement of prior ADP; \>50% decrease VSM; Neut \>1500/mm\^3 or \>50% increase; Plt \>100,000/mm\^3 or \>50% increase; Hb \>11.0 g/dL or \>50% increase (no transfusion). All CR criteria but persistent anemia or thrombocytopenia was PR. MRD: Lymph \>0.01% of blood/BM WBCs.

Time frame:
From first CR or PR up to detectable MRD or disease occurrence/PD, whichever occurred first (up to 92 months)
Reported as:
Median · Years
Duration of Response (DOR)
YearsRituximab + Fludarabine + Cyclophosphamide
Duration of Response (DOR)NA (NA to NA)
SecondaryPercentage of Participants With Cluster of Differentiation (CD) 38 Cells >/=30% in Peripheral Blood

Percentages of participants with CD38 expression by \>/=30% of CLL cells during the Induction Phase, Maintenance Phase, and Follow-Up were reported.

Time frame:
Post-Induction Phase: at 6 months; during Maintenance Phase: at Cycles 9, 12, 15, 18 (cycle length = 2 months); during Follow-Up: at Follow-Up Months 6, 12, 18, 24, 30, 36
Reported as:
Number · Percentage of Participants
Percentage of Participants With Cluster of Differentiation (CD) 38 Cells >/=30% in Peripheral Blood
Percentage of ParticipantsRituximab + Fludarabine + Cyclophosphamide
Post-IP47.6
MP (9 Cycles)44.4
MP (12 Cycles)45.5
MP (15 Cycles)47.6
MP (18 Cycles)47.4
6 Months FU66.7
12 Months FU45.7
18 Months FU100.0
24 Months FU41.4
30 Months FU50.0
36 Months FU35.5
SecondaryPercentage of Participants With Genetic Abnormalities

Percentages of participants with genetic abnormalities (deletion 6q, deletion 11q22-q23, deletion p53, trisomy 12, and deletion 13q14) in the course of the disease during the Induction Phase and Maintenance Phase were reported.

Time frame:
Post-Induction Phase: at 6 months; during Maintenance Phase: at Cycles 9, 12, 15, 18 (cycle length = 2 months)
Reported as:
Number · Percentage of Participants
Percentage of Participants With Genetic Abnormalities
Percentage of ParticipantsRituximab + Fludarabine + Cyclophosphamide
Post-IP: Deletion 6q3.6
Post-IP: Deletion 11q22-q2326.2
Post-IP: Deletion p534.8
Post-IP: Trisomy 1215.5
Post-IP: Deletion 13q1450.0
MP (9C): Deletion 6q4.3
MP (9C): Deletion 11q22-q2325.5
MP (9C): Deletion p530.0
MP (9C): Trisomy 1217.0
MP (9C): Deletion 13q1455.3
MP (12C): Deletion 6q3.0
MP (12C): Deletion 11q22-q2321.2
MP (12C): Deletion p530.0
MP (12C): Trisomy 12 (n= 33)21.2
MP (12C): Deletion 13q1451.5
MP (15C): Deletion 6q4.5
MP (15C): Deletion 11q22-q2331.8
MP (15C): Deletion p530.0
MP (15C): Trisomy 1218.2
MP (15C): Deletion 13q1459.1
MP (18C): Deletion 6q3.4
MP (18C): Deletion 11q22-q2323.7
MP (18C): Deletion p530.0
MP (18C): Trisomy 1218.6
MP (18C): Deletion 13q1449.2
SecondaryPercentage of Participants With Positive and Negative Zeta-Chain-Associated Protein Kinase 70 (ZAP-70) Expression

Percentages of participants with positive and negative ZAP-70 expression during the Induction Phase, Maintenance Phase, and Follow-Up were reported. Positive ZAP-70 was defined as ZAP-70 expression by \>/=20% of CLL cells. Negative ZAP-70 was defined as ZAP-70 expression by \<20% of CLL cells.

Time frame:
Post-Induction Phase: at 6 months; during Maintenance Phase: at Cycles 9, 12, 15, 18 (cycle length = 2 months); during Follow-Up: at Follow-Up Months 6, 12, 18, 24, 30, 36
Reported as:
Number · Percentage of Participants
Percentage of Participants With Positive and Negative Zeta-Chain-Associated Protein Kinase 70 (ZAP-70) Expression
Percentage of ParticipantsRituximab + Fludarabine + Cyclophosphamide
Post-IP: Positive57.3
Post-IP: Negative42.7
MP (9 Cycles): Positive57.5
MP (9 Cycles): Negative42.5
MP (12 Cycles): Positive62.1
MP (12 Cycles): Negative37.9
MP (15 Cycles): Positive57.1
MP (15 Cycles): Negative42.9
MP (18 Cycles): Positive54.9
MP (18 Cycles): Negative45.1
6 Months FU: Positive63.6
6 Months FU: Negative36.4
12 Months FU: Positive60.0
12 Months FU: Negative40.0
18 Months FU: Positive100.0
18 Months FU: Negative0.0
24 Months FU: Positive59.3
24 Months FU: Negative40.7
30 Months FU: Positive100.0
30 Months FU: Negative0.0
36 Months FU: Positive57.1
36 Months FU: Negative42.9
SecondaryPercentage of Participants With Immunoglobulin Heavy Locus (IgH) Rearrangement

Percentages of participants with IgH rearrangement during the Induction Phase, Maintenance Phase, and Follow-Up were reported.

Time frame:
Post-Induction Phase: at 6 months; during Maintenance Phase: at Cycles 9, 12, 15, 18 (cycle length = 2 months); during Follow-Up: at Follow-Up Months 6, 12, 18, 24, 30, 36
Reported as:
Number · Percentage of Participants
Percentage of Participants With Immunoglobulin Heavy Locus (IgH) Rearrangement
Percentage of ParticipantsRituximab + Fludarabine + Cyclophosphamide
Post-IP36.2
MP (9 Cycles)37.1
MP (12 Cycles)20.0
MP (15 Cycles)29.4
MP (18 Cycles)33.3
6 Months FU100.0
12 Months FU37.9
18 Months FU50.0
24 Months FU33.3
30 Months FU0.0
36 Months FU45.8

Adverse events

Collected over Baseline through end of Follow-Up (up to 92 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab + Fludarabine + Cyclophosphamide—35/86 (40.7%)82/86 (95.3%)
Most frequent serious events
Showing 10 of 36
Most frequent serious events
EventRituximab + Fludarabine + Cyclophosphamide
Febrile neutropeniaBlood and lymphatic system disorders8/86
PneumoniaInfections and infestations7/86
PyrexiaGeneral disorders6/86
InfluenzaInfections and infestations2/86
Respiratory tract infectionInfections and infestations2/86
AnaemiaBlood and lymphatic system disorders1/86
NeutropeniaBlood and lymphatic system disorders1/86
Myocardial infarctionCardiac disorders1/86
Crohn's diseaseGastrointestinal disorders1/86
DiarrhoeaGastrointestinal disorders1/86
Most frequent other events
Showing 10 of 19
Most frequent other events
EventRituximab + Fludarabine + Cyclophosphamide
NeutropeniaBlood and lymphatic system disorders52/86
PyrexiaGeneral disorders31/86
NasopharyngitisInfections and infestations27/86
NauseaGastrointestinal disorders26/86
LymphopeniaBlood and lymphatic system disorders24/86
ThrombocytopeniaBlood and lymphatic system disorders18/86
DiarrhoeaGastrointestinal disorders16/86
LeukopeniaBlood and lymphatic system disorders15/86
VomitingGastrointestinal disorders15/86
AstheniaGeneral disorders14/86

Baseline characteristics

Intent-to-Treat (ITT) Population included all participants who received at least one dose of study drug and met inclusion/exclusion criteria.

Age, Continuous
Age, Continuous(Years)Rituximab + Fludarabine + Cyclophosphamide
Mean57.92 ± 7.87
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab + Fludarabine + Cyclophosphamide
Female27
Male57
08

Study locations

33 sites
  • Hospital De Txagorritxu; Servicio de Hematologia
    Vitoria, Alava 01009, Spain
  • Hospital Universitario Puerta del Mar; Servicio de Hematologia
    Cádiz, Cadiz 11009, Spain
  • Hospital de Jerez de la Frontera; Servicio de Hematologia
    Jerez de La Frontera, Cadiz 11407, Spain
  • Hospital Universitario Marques de Valdecilla; Servicio de Hematologia
    Santander, Cantabria 39008, Spain
  • Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Hematologia
    La Coruna, LA Coruña 15006, Spain
  • Fundacion Hospital de Alcorcon; Servicio de Hematologia
    Alcorcon, Madrid 28922, Spain
  • Hosital Universitario de Mostoles;Servicio de Hematologia
    Mostoles, Madrid 28935, Spain
  • Hospital Francesc de Borja; Servicio de Hematologia
    Gandia, Valencia 46702, Spain
  • Hospital de Sagunto; Servicio de Hematologia
    Sagunto, Valencia 46520, Spain
  • Hospital de Basurto; Servicio de Hematologia
    Bilbao, Vizcaya 48013, Spain
  • Hospital Universitario Infanta Cristina; Servicio de Hematologia
    Badajoz, 06080, Spain
  • Hospital Duran i Reynals; Servicio de Hematologia
    Barcelona, 08907, Spain
  • Hospital San Pedro De Alcantara; Servicio de Hematologia
    Caceres, 10003, Spain
  • Hospital General de Castellon; Servicio de Hematologia
    Castellon, 12004, Spain
  • Hospital Universitario Virgen de las Nieves; Servicio de Hematologia
    Granada, 18014, Spain
  • Hospital General Universitario Gregorio Marañon; Servicio de Hematología
    Madrid, 28007, Spain
  • Hospital Ramon y Cajal; Servicio de Hematologia
    Madrid, 28034, Spain
  • Hospital Universitario Clínico San Carlos; Servicio de Hematología
    Madrid, 28040, Spain
  • Hospital Univ. 12 de Octubre; Servicio de Hematologia
    Madrid, 28041, Spain
  • Hospital Universitario la Paz; Servicio de Hematologia
    Madrid, 28046, Spain
  • HOSPITAL DE MADRID NORTE SANCHINARRO- CENTRO INTEGRAL ONCOLOGICO CLARA CAMPAL; Servicio Hematologia
    Madrid, 28050, Spain
  • Hospital Universitario Puerta de Hierro; Servicio de Hematologia
    Madrid, 28222, Spain
  • Hospital Universitario Principe de Asturias; Servicio de Hematología
    Madrid, 28805, Spain
  • Hospital Universitario de Getafe; Servico de Hematologia
    Madrid, 28905, Spain
  • Hospital Clinico Universitario Virgen de la Victoria; Servicio de Hematologia
    Malaga, 29010, Spain
  • Hospital General Universitario J.M Morales Meseguer; Servicio de Hematología
    Murcia, 30008, Spain
  • Hospital Clinico Universitario de Salamanca;Servicio de Hematologia
    Salamanca, 37007, Spain
  • Hospital General Universitario de Valencia; Servicio de Hematologia
    Valencia, 46014, Spain
  • Hospital Arnau de Vilanova (Valencia) Servicio de Hematologia
    Valencia, 46015, Spain
  • Hospital Universitario Dr. Peset; Servicio de Hematologia
    Valencia, 46017, Spain
  • Hospital Universitario la Fe; Servicio de Hematologia
    Valencia, 46026, Spain
  • Hospital Clinico Universitario Lozano Blesa; Servicio de Hematologia
    Zaragoza, 50009, Spain
  • Hospital Universitario Miguel Servet; Servicio Hematologia
    Zaragoza, 50009, Spain
09

References and documents

Publications

  • Garcia-Marco JA, Jimenez JL, Recasens V, Zarzoso MF, Gonzalez-Barca E, De Marcos NS, Ramirez MJ, Parraga FJP, Yanez L, De La Serna Torroba J, Malo MDG, Ariznavarreta GD, Persona EP, Guinaldo MAR, De Paz Arias R, Llanos EB, Jarque I, Valle MDCF, Tatay AC, De Oteyza JP, Martin EMD, Fernandez IP, Martinez RM, Costa MAA, Champ D, Suarez JG, Diaz MG, Ferrer S, Carbonell F, Garcia-Vela JA; GELLC Study Group. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance. Haematologica. 2019 Nov;104(11):2249-2257. doi: 10.3324/haematol.2018.204891. Epub 2019 Mar 19. PubMed 30890600 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2007 to primary completion in May 2016, 101 months.

Results were first posted in Jan 2019, 2 years 7 months after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 101 months is above that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2007
First posted
Oct 17, 2007
StartActual
Nov 21, 2007
Primary completionActual
May 20, 2016
CompletionActual
May 20, 2016
Results first posted
Jan 16, 2019
Last update
Jan 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00545714
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 17, 2007
Start date
Nov 21, 2007
Primary completion
May 20, 2016
Completion
May 20, 2016
Results posted
Jan 16, 2019
Last update
Jan 16, 2019

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cyclophosphamide · Fludarabine · Rituximab

Start the discussion